Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:CPRX
- CUSIP: N/A
- Web: www.catalystpharma.com
Capitalization:- Market Cap: $203.78 million
- Outstanding Shares: 84,554,000
Average Prices:- 50 Day Moving Avg: $2.72
- 200 Day Moving Avg: $2.28
- 52 Week Range: $0.94 - $3.20
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.72
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.40 per share
- Price / Book: 6.08
Profitability:- EBIDTA: ($16,440,000.00)
- Return on Equity: -44.65%
- Return on Assets: -42.03%
Debt:- Current Ratio: 19.43%
- Quick Ratio: 19.43%
Misc:- Average Volume: 976,134 shs.
- Beta: 1.6
- Short Ratio: 5.67
Frequently Asked Questions for Catalyst Pharmaceuticals (NASDAQ:CPRX)
What is Catalyst Pharmaceuticals' stock symbol?
Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."
How were Catalyst Pharmaceuticals' earnings last quarter?
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its earnings results on Wednesday, August, 9th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. View Catalyst Pharmaceuticals' Earnings History.
When will Catalyst Pharmaceuticals make its next earnings announcement?
Where is Catalyst Pharmaceuticals' stock going? Where will Catalyst Pharmaceuticals' stock price be in 2017?
4 brokerages have issued 1-year price objectives for Catalyst Pharmaceuticals' stock. Their predictions range from $5.00 to $6.00. On average, they anticipate Catalyst Pharmaceuticals' share price to reach $5.50 in the next year. View Analyst Ratings for Catalyst Pharmaceuticals.
Who are some of Catalyst Pharmaceuticals' key competitors?
Some companies that are related to Catalyst Pharmaceuticals include Bellicum Pharmaceuticals (BLCM), GlycoMimetics (GLYC), Selecta Biosciences (SELB), Mersana Therapeutics (MRSN), Kura Oncology (KURA), Geron Corporation (GERN), Ra Pharmctl (RARX), Corbus Pharmaceuticals Holdings (CRBP), BioSpecifics Technologies Corp (BSTC), BioTime (BTX), CymaBay Therapeutics (CBAY), Merus N.V. (MRUS), Minerva Neurosciences (NERV), Rigel Pharmaceuticals (RIGL), Forward Pharma A/S (FWP), Edge Therapeutics (EDGE), Stemline Therapeutics (STML) and Athersys (ATHX).
Who are Catalyst Pharmaceuticals' key executives?
Catalyst Pharmaceuticals' management team includes the folowing people:
- Patrick James McEnany, Chairman of the Board, President, Chief Executive Officer
- Alicia Grande CPA, Chief Financial Officer, Vice President, Treasurer
- Steven R. Miller Ph.D., Chief Operating Officer, Chief Scientific Officer
- David D. Muth, Executive Vice President, Chief Commercial Officer
- M. Douglas Winship, Vice President - Regulatory Operations
- David J. Caponera, Vice President - Patient Advocacy & Reimbursement
- Bernardino Mosquera M.D., Vice President - Clinical Operations
- Charles B. O'Keeffe, Lead Independent Director
- Gary Ingenito M.D., Chief Medical Officer
- Richard J. Daly, Director
Who owns Catalyst Pharmaceuticals stock?
Catalyst Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Broadfin Capital LLC (8.69%), Vanguard Group Inc. (4.00%), JPMorgan Chase & Co. (1.83%), State Street Corp (1.11%), Kennedy Capital Management Inc. (1.10%) and Northern Trust Corp (0.96%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus, M Douglas Winship, Patrick J Mcenany, Philip H Coelho and Steve Miller. View Institutional Ownership Trends for Catalyst Pharmaceuticals.
Who sold Catalyst Pharmaceuticals stock? Who is selling Catalyst Pharmaceuticals stock?
Catalyst Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Berson & Corrado Investment Advisors LLC, Candriam Luxembourg S.C.A. and Tanaka Capital Management Inc.. View Insider Buying and Selling for Catalyst Pharmaceuticals.
Who bought Catalyst Pharmaceuticals stock? Who is buying Catalyst Pharmaceuticals stock?
Catalyst Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., State Street Corp, Northern Trust Corp, Kennedy Capital Management Inc., AJO LP, Vanguard Group Inc., FMR LLC and TIAA CREF Investment Management LLC. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus, Patrick J Mcenany, Philip H Coelho and Steve Miller. View Insider Buying and Selling for Catalyst Pharmaceuticals.
How do I buy Catalyst Pharmaceuticals stock?
Shares of Catalyst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Catalyst Pharmaceuticals' stock price today?
One share of Catalyst Pharmaceuticals stock can currently be purchased for approximately $2.43.
MarketBeat Community Rating for Catalyst Pharmaceuticals (NASDAQ CPRX)MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Catalyst Pharmaceuticals (NASDAQ:CPRX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $5.50 (126.34% upside) |
Analysts' Ratings History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/5/2017 | SunTrust Banks, Inc. | Reiterated Rating | Buy | $5.00 | High |  |
| 8/10/2017 | Roth Capital | Set Price Target | Buy | $5.00 | Low | |
| 8/7/2017 | Piper Jaffray Companies | Set Price Target | Buy | $6.00 | Low | |
| 3/20/2017 | HC Wainwright | Reiterated Rating | Buy | $6.00 | Low | |
(Data available from 9/19/2015 forward)
Earnings History for Catalyst Pharmaceuticals (NASDAQ:CPRX)Earnings History by Quarter for Catalyst Pharmaceuticals (NASDAQ CPRX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($0.06) | | | | | N/A | |
| 8/9/2017 | Q2 2017 | ($0.06) | ($0.05) | | | View | Listen | |
| 5/10/2017 | Q1 2017 | ($0.06) | ($0.06) | | | View | N/A | |
| 3/15/2017 | Q4 2016 | ($0.07) | ($0.05) | | | View | N/A | |
| 11/9/2016 | Q316 | ($0.06) | ($0.05) | | | View | Listen | |
| 8/9/2016 | Q216 | ($0.08) | ($0.06) | | | View | N/A | |
| 5/10/2016 | Q116 | ($0.07) | ($0.07) | | | View | N/A | |
| 3/15/2016 | Q415 | ($0.07) | ($0.07) | | | View | N/A | |
| 8/10/2015 | Q215 | ($0.08) | ($0.06) | | | View | Listen | |
| 5/11/2015 | Q115 | ($0.08) | ($0.06) | | | View | N/A | |
| 3/16/2015 | Q414 | ($0.07) | ($0.06) | | | View | N/A | |
| 11/14/2014 | Q314 | ($0.06) | ($0.06) | | | View | N/A | |
| 8/14/2014 | Q214 | ($0.08) | ($0.05) | | | View | N/A | |
| 3/19/2014 | Q413 | ($0.07) | ($0.02) | | | View | N/A | |
| 11/14/2013 | Q3 | ($0.07) | ($0.07) | | | View | N/A | |
| 8/15/2013 | Q213 | ($0.07) | ($0.06) | | | View | N/A | |
| 11/15/2012 | Q312 | | ($0.08) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)2017 EPS Consensus Estimate: ($0.24)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.06) | ($0.06) | ($0.06) |
| Q2 2017 | 1 | ($0.06) | ($0.06) | ($0.06) |
| Q3 2017 | 1 | ($0.06) | ($0.06) | ($0.06) |
| Q4 2017 | 2 | ($0.07) | ($0.05) | ($0.06) |
(Data provided by Zacks Investment Research)
Dividend History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Catalyst Pharmaceuticals (NASDAQ:CPRX)Insider Ownership Percentage: 8.79%
Institutional Ownership Percentage: 40.15%
Insider Trades by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/5/2017 | Patrick J Mcenany | Insider | Buy | 20,000 | $2.58 | $51,600.00 | |
| 7/12/2016 | Charles B O'keeffe | Director | Buy | 20,000 | $0.81 | $16,200.00 | |
| 6/17/2016 | Philip H Coelho | Director | Buy | 15,000 | $0.76 | $11,400.00 | |
| 6/14/2016 | Donald A Denkhaus | Director | Buy | 50,000 | $0.65 | $32,500.00 | |
| 6/14/2016 | Patrick J Mcenany | CEO | Buy | 105,300 | $0.65 | $68,445.00 | |
| 4/26/2016 | Charles B O'keeffe | Director | Buy | 20,000 | $0.60 | $12,000.00 | |
| 4/26/2016 | Patrick J Mcenany | CEO | Buy | 50,000 | $0.65 | $32,500.00 | |
| 3/17/2016 | Philip H Coelho | Director | Buy | 10,000 | $1.06 | $10,600.00 | |
| 3/16/2016 | Charles B O'keeffe | Director | Buy | 10,000 | $1.11 | $11,100.00 | |
| 1/11/2016 | Steve Miller | COO | Buy | 7,933 | $1.80 | $14,279.40 | |
| 1/8/2016 | Charles B O'keeffe | Director | Buy | 5,000 | $1.94 | $9,700.00 | |
| 1/7/2016 | Donald A Denkhaus | Director | Buy | 25,000 | $2.03 | $50,750.00 | |
| 12/28/2015 | Patrick J Mcenany | CEO | Buy | 25,000 | $2.39 | $59,750.00 | |
| 12/23/2015 | Charles B O'keeffe | Director | Buy | 5,000 | $2.41 | $12,050.00 | |
| 11/19/2015 | Charles B O'keeffe | Director | Buy | 5,000 | $2.30 | $11,500.00 | |
| 10/23/2015 | M Douglas Winship | VP | Sell | 22,800 | $3.34 | $76,152.00 | |
| 10/1/2015 | Patrick J Mcenany | CEO | Buy | 10,000 | $2.81 | $28,100.00 | |
| 5/1/2015 | David D Muth | EVP | Buy | 1,700 | $3.20 | $5,440.00 | |
| 4/30/2015 | Charles B O'keeffe | Director | Buy | 10,000 | $3.29 | $32,900.00 | |
| 4/28/2015 | David D Muth | EVP | Buy | 2,000 | $3.55 | $7,100.00 | |
| 4/27/2015 | Donald A Denkhaus | Director | Buy | 15,000 | $3.71 | $55,650.00 | |
| 4/27/2015 | Patrick J Mcenany | CEO | Buy | 5,000 | $3.79 | $18,950.00 | |
| 4/24/2015 | Charles B O'keeffe | Director | Buy | 5,000 | $3.80 | $19,000.00 | |
| 3/27/2015 | Donald A Denkhaus | Director | Buy | 5,000 | $4.17 | $20,850.00 | |
| 1/20/2015 | David D Muth | EVP | Buy | 21,000 | $2.96 | $62,160.00 | |
| 1/13/2015 | Charles B O'keeffe | Director | Buy | 10,000 | $3.00 | $30,000.00 | |
| 1/8/2015 | Patrick J Mcenany | CEO | Buy | 50,000 | $2.80 | $140,000.00 | |
| 10/3/2014 | David D Muth | VP | Buy | 10,000 | $2.65 | $26,500.00 | |
| 6/4/2014 | Steve Miller | COO | Buy | 100,000 | $2.17 | $217,000.00 | |
| 5/21/2014 | Patrick Mcenany | CEO | Buy | 25,000 | $1.89 | $47,250.00 | |
| 5/19/2014 | Charles O'keeffe | Director | Buy | 10,000 | $1.83 | $18,300.00 | |
| 4/16/2014 | Charles O'keeffe | Director | Buy | 5,000 | $2.02 | $10,100.00 | |
| 2/7/2014 | Patrick Mcenany | CEO | Buy | 25,000 | $1.82 | $45,500.00 | |
| 2/5/2014 | Charles O'keeffe | Director | Buy | 10,000 | $1.81 | $18,100.00 | |
| 10/23/2013 | David S Tierney | Director | Buy | 8,000 | $2.03 | $16,240.00 | |
| 10/21/2013 | Charles B O'keeffe | Director | Buy | 10,000 | $1.84 | $18,400.00 | |
| 10/21/2013 | Patrick J Mcenany | CEO | Buy | 50,000 | $1.59 | $79,500.00 | |
| 2/19/2013 | Patrick J Mcenany | CEO | Buy | 50,000 | $0.46 | $23,000.00 | |
| 12/17/2012 | Patrick J Mcenany | CEO | Buy | 100,000 | $0.45 | $45,000.00 | |
| 12/8/2012 | Biomarin Pharmaceutical Inc | Major Shareholder | Buy | 5,000,000 | $0.75 | $3,750,000.00 | |
| 11/15/2012 | Patrick J Mcenany | CEO | Buy | 100,000 | $0.42 | $42,000.00 | |
| 11/15/2012 | Philip H Coelho | Director | Buy | 24,000 | $0.41 | $9,840.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Latest Headlines for Catalyst Pharmaceuticals (NASDAQ:CPRX)
| Source: |
|
| Date | Headline |
|---|
 | Catalyst (CPRX) Focused on Two Lead Pipeline Candidates
finance.yahoo.com - September 18 at 5:28 PM |
 | Catalyst Pharmaceuticals, Inc. (CPRX) Insider Patrick J. Mcenany Purchases 20,000 Shares
www.americanbankingnews.com - September 5 at 4:46 PM |
| Catalyst Pharmaceuticals' (CPRX) Buy Rating Reiterated at SunTrust Banks, Inc.
www.americanbankingnews.com - September 5 at 9:42 AM |
| Analysts Expect Catalyst Pharmaceuticals, Inc. (CPRX) to Announce -$0.06 Earnings Per Share
www.americanbankingnews.com - September 3 at 10:24 PM |
 | Catalyst Pharmaceuticals Provides Update on the Status of its ... - Nasdaq
www.nasdaq.com - August 31 at 10:22 PM |
 | Catyalyst Pharma (CPRX) Provides Update on the Status of its Firdapse; Sees NDA Submitted in First Quarter of 2018
www.streetinsider.com - August 31 at 5:21 PM |
 | Catalyst Pharmaceuticals Provides Update on the Status of its Firdapse Development Activities - GlobeNewswire (press release)
globenewswire.com - August 30 at 6:31 PM |
| Catalyst Pharmaceuticals Provides Update on the Status of its Firdapse Development Activities
finance.yahoo.com - August 30 at 6:31 PM |
| Catalyst (CPRX) Focused on Development of Pipeline Candidates
www.nasdaq.com - August 15 at 6:12 PM |
| Catalyst Pharmaceuticals, Inc. to Post Q4 2017 Earnings of ($0.05) Per Share, SunTrust Banks Forecasts (NASDAQ:CPRX)
www.americanbankingnews.com - August 14 at 6:42 AM |
| Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 10 at 11:04 PM |
 | Catalyst Pharmaceutical Partners' (CPRX) CEO Patrick McEnany on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 10 at 6:46 PM |
| Catalyst Pharmaceuticals, Inc. (CPRX) Given a $5.00 Price Target at Roth Capital
www.americanbankingnews.com - August 10 at 3:22 PM |
| Catalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update - Nasdaq
www.nasdaq.com - August 9 at 5:38 PM |
| Catalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 9 at 5:38 PM |
| Catalyst reports 2Q loss
finance.yahoo.com - August 9 at 5:38 PM |
| What's in Store for Catalyst (CPRX) This Earnings Season? - Nasdaq
www.nasdaq.com - August 9 at 3:15 AM |
 | What's in Store for Catalyst (CPRX) This Earnings Season?
www.zacks.com - August 7 at 10:54 PM |
| Catalyst Pharmaceuticals, Inc. (CPRX) Given a $6.00 Price Target by Piper Jaffray Companies Analysts
www.americanbankingnews.com - August 7 at 6:20 PM |
| Catalyst Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Th
www.nasdaq.com - August 2 at 4:18 AM |
| Catalyst Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10th, 2017
finance.yahoo.com - August 1 at 6:12 PM |
| Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - July 31 at 8:14 AM |
| -$0.06 Earnings Per Share Expected for Catalyst Pharmaceuticals, Inc. (CPRX) This Quarter
www.americanbankingnews.com - July 29 at 7:46 AM |
| Catalyst Pharmaceuticals, Inc. (CPRX) Short Interest Down 16.0% in July
www.americanbankingnews.com - July 28 at 1:25 AM |
| Short Interest in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Rises By 213.4%
www.americanbankingnews.com - July 14 at 7:04 AM |
 | 10 Biggest Mid-Day Losers For Thursday | Benzinga - Benzinga
www.benzinga.com - July 13 at 6:42 PM |
 | Commit To Purchase Catalyst Pharmaceuticals At $2.50, Earn 73% Annualized Using Options - TheStreet.com
www.thestreet.com - July 12 at 11:12 PM |
| Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - July 12 at 9:02 PM |
 | Biotech Stocks Ride Momentum in Anticipation of Favorable Governmental Policy Environment
www.bizjournals.com - July 12 at 6:09 PM |
| Today's Research Reports on Trending Tickers: Nektar Therapeutics and Catalyst Pharmaceuticals Inc.
finance.yahoo.com - July 12 at 6:09 PM |
| Catalyst Pharmaceuticals, Inc. (CPRX) Expected to Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - July 5 at 11:48 AM |
| Why is Catalyst Pharmaceuticals' Stock Up 160% this Year?
www.zacks.com - June 28 at 5:25 PM |
| Catalyst Pharmaceuticals Joins Russell 3000 Index - GlobeNewswire (press release)
globenewswire.com - June 26 at 10:18 PM |
| Catalyst Pharmaceuticals Joins Russell 3000 Index
finance.yahoo.com - June 26 at 5:16 PM |
| Why Is Catalyst Pharmaceuticals (CPRX) Up 25.5% Since the Last Earnings Report?
www.nasdaq.com - June 14 at 5:21 PM |
| -$0.06 EPS Expected for Catalyst Pharmaceuticals Inc (CPRX) This Quarter
www.americanbankingnews.com - June 9 at 12:06 AM |
| Catalyst Pharmaceuticals (CPRX) Shares March Higher, Can It Continue?
www.nasdaq.com - June 8 at 1:46 AM |
| Catalyst Pharmaceuticals (CPRX) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 1:46 AM |
| Three Junior Biotechs Ready to Run
finance.yahoo.com - June 7 at 3:41 PM |
| Catalyst Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - June 1 at 10:05 PM |
| Catalyst Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference
finance.yahoo.com - June 1 at 5:03 PM |
| Catalyst Pharmaceuticals Inc (CPRX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 22 at 4:28 PM |
| Catalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV Symposium - GlobeNewswire (press release)
globenewswire.com - May 19 at 8:35 AM |
| Catalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV Symposium - Nasdaq
www.nasdaq.com - May 18 at 11:01 AM |
| Catalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV Symposium
finance.yahoo.com - May 17 at 11:29 AM |
| Catalyst Pharmaceuticals Receives 2017 Beacon Council Award for Contributions in Life Sciences & Healthcare
finance.yahoo.com - May 12 at 5:00 PM |
| Catalyst Pharmaceuticals Inc (CPRX) Issues Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - May 11 at 5:30 PM |
| Catalyst Pharmaceuticals (CPRX) Posts Loss as Expected in Q1
www.zacks.com - May 11 at 5:04 PM |
| Investor Network: Catalyst Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 11 at 5:04 PM |
| Catalyst Pharmaceuticals Announces Poster Presentation of MuSK ... - GlobeNewswire (press release)
globenewswire.com - May 10 at 9:48 PM |
Catalyst Pharmaceuticals (CPRX) Chart for Tuesday, September, 19, 2017
